PrECOG

What PrECOG does

PrECOG is a not-for-profit cancer research organization operating as a limited liability company, formed in 2006 by the ECOG Research and Education Foundation to conduct multi-center oncology clinical trials outside of federal NCTN funding while supporting the scientific mission of the ECOG-ACRIN Cancer Research Group. Headquartered in Philadelphia with 11-50 employees, PrECOG provides end-to-end clinical trial management services including regulatory sponsorship under INDs, central registration and randomization, electronic data capture (EDC), independent Data Safety Monitoring Board oversight, and centralized biobanking through the Central Biorepository and Pathology Facility and Leukemia Bank at MD Anderson Cancer Center. Its operational infrastructure spans 400+ participating clinical sites across 21 countries, including NCI-designated cancer centers, academic medical centers, and community oncology practices, many governed by master service agreements that accelerate study activation.

The organization executes Phase 1, 2, and 3 trials across breast, thoracic, gastrointestinal, genitourinary, lymphoma, leukemia, and multiple myeloma indications under Standard Operating Procedures aligned with FDA regulations and ICH/GCP guidelines. Named industry partners include Pfizer (PALLAS, BRACELET-1), AstraZeneca/Medimmune (PrE0505, DREAM3R), Genentech/AbbVie (PrE0405), Merck KGaA, and Oncolytics Biotech. PrECOG's research has been published in the New England Journal of Medicine, Nature Medicine, JAMA Oncology, the Journal of Clinical Oncology, Clinical Cancer Research, and the Lancet Oncology, and is regularly presented at ASCO and ASH annual meetings.

PrECOG is funded entirely outside the public health system through study-by-study research collaborations and partnership agreements with pharmaceutical sponsors and academic research consortia. Pricing is not publicly disclosed and is negotiated on a study-by-study basis. Industry sponsors typically provide study drug, funding, or co-development support in exchange for data suitable for regulatory submissions and high-impact publications. Academic investigators access PrECOG's site network and operational infrastructure as participating investigative sites, while the organization enters into joint sponsorships with international cooperative groups such as ABCSG, BIG, GBG, NSABP, AFT, Breast Cancer Trials (ANZ), Fondazione Michelangelo, SOLTI, Unicancer, and the University of Sydney/NHMRC Clinical Trials Centre.

Name

PrECOG

Legal name

PrECOG, LLC.

Website

https://precogllc.org

Company type

Private

Founded year

2006

Operating status

Operating

Headcount range

11–50 employees

Short description

PrECOG is a not-for-profit cancer research LLC founded in 2006 by the ECOG Research and Education Foundation that runs multi-center oncology clinical trials (Phase 1-3) across 400+ sites in 21 countries. It provides regulatory sponsorship, data management, biobanking, and DSMB oversight for pharmaceutical industry partners and academic investigators.

Ownership category

akta.pro rank

Product category

Clinical Trial Management Services

NAICS

Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Clinical Development (Phase I–III Trial Design & Execution) (HLAIALAE)

akta.pro secondary industries

Clinical Trial Site Operations & Study Coordination (HLAGACAE), Regulatory Strategy & IND/NDA/BLA Submissions Support (HLAIALAH), Clinical Trials Authorization & Oversight (GCP) (HLAJADAF), Clinical Research & Trial Central Laboratories (HLAFAMAL)

Keywords

• Oncology clinical trials
• Clinical trial management
• Cancer research services
• Regulatory sponsorship
• Biobank services

Headquarters

HQ city

Philadelphia

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Industry Research Collaborations and Partnerships: PrECOG enters into research collaborations with cancer research groups and industry partners in shared or transferred research responsibilities. Industry partners provide study drug, funding, or co-development support in exchange for data contributing to regulatory filings or publications. Examples include Pfizer (palbociclib/PALLAS), AstraZeneca/Medimmune (durvalumab/DREAM3R), Genentech/AbbVie (venetoclax/PrE0405), Oncolytics Biotech (pelareorep/BRACELET-1), and Merck KGaA (avelumab/BRACELET-1).
2. External Funding and Grants: PrECOG is funded entirely outside of the public health system. While not explicitly described as government-funded, PrECOG supports the goals of ECOG-ACRIN Cancer Research Group and operates with an operational structure separate from the NCTN. Some trials may receive NCI review and approval or use NCTN site networks.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels7 records

Core offering

PrECOG designs, implements, and manages multi-center oncology clinical trials across all phases (1-3), acting as regulatory sponsor under an IND. It provides end-to-end clinical trial services including study concept development, site activation across its network of academic and community research centers, central registration/randomization, electronic data capture, independent Data Safety Monitoring Board oversight, and central biorepository/biobank services located at MD Anderson Cancer Center.

Product overview

PrECOG is a not-for-profit cancer research organization (limited liability company) formed in 2006 by the ECOG Research and Education Foundation. It offers a comprehensive suite of clinical trial management services rather than a software product. The portfolio includes: Clinical Trial Management (regulatory sponsorship, central registration/randomization, EDC); Research Development Services; a network of trial sites (U.S. and international); a Central Data Safety Monitoring Board; biobank services through the Central Biorepository and Pathology Facility and Leukemia Bank at MD Anderson; and collaborative research models with industry partners. PrECOG supports trials across all phases (1-3) in oncology indications including breast, thoracic, GI, genitourinary, lymphoma, leukemia, and multiple myeloma.

Differentiator

Problem solved

Functional benefit

Products and services

• Clinical Trial Management Full-service clinical trial oversight and management including all sponsor-related responsibilities under an Investigational New Drug application, central registration/randomization, electronic data capture, and end-to-end study operations for oncology trials across all phases.
• Research Development Services Development of clinical trial concepts aligned with ECOG-ACRIN Cancer Research Group scientific committees, with collaborative relationships with industry partners for novel therapy research across breast, thoracic, GI, genitourinary, leukemia, lymphoma, and multiple myeloma indications.
• Study Site Network Established network of clinical trial sites including U.S. and international research networks, community and NCI-designated cancer centers, academic institutions, and individual research practices with extensive oncology research experience. Many sites have master service agreements with PrECOG to facilitate rapid study activation.
• Central Data Safety Monitoring Board Independent safety oversight service for clinical trials monitoring subject safety, scientific integrity, data validity, accrual timelines, and data quality. The DSMB operates when determined required by study risk profile.
• Central Biorepository and Pathology Facility (CBPF) Biobank services at MD Anderson Cancer Center for collection, processing, preservation, storage, quality control, and distribution of solid tumor tissue and biological fluids for clinical translational research.
• Leukemia Bank Specialized biobank for receipt and processing of biospecimens from patients on PrECOG leukemia trials, located at MD Anderson Cancer Center.
• Regulatory Sponsor Services Regulatory sponsorship for clinical trials compliant with FDA regulations and ICH/GCP guidelines, with Standard Operating Procedures governing all trial activities and oversight of all sponsor-related responsibilities under an IND.

Quantifiable outcome

• Phase 3 PATINA trial (NEJM 2026): median PFS of 44.3 months with palbociclib vs 29.1 months control in HR+, HER2+ metastatic breast cancer — a 15-month improvement
• +4 more outcomes

Named customers10 records

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

18 partnerships are on record, tiered core.

• Oncolytics Biotech Inc.coreStrategic or Co-development Partner · 22 October 2019PrECOG is running the BRACELET-1 (PrE0113) study evaluating pelareorep, an intravenously delivered immuno-oncolytic virus, in combination with paclitaxel and avelumab for HR+ HER2- metastatic breast cancer. Kathy Miller, MD, from Indiana University serves as principal investigator. The study was funded by Oncolytics Biotech, Pfizer, and Merck KGaA.
• ECOG-ACRIN Cancer Research GroupcoreStrategic or Co-development PartnerPrECOG was formed in 2006 by the ECOG Research and Education Foundation to support the overall purpose of ECOG-ACRIN Cancer Research Group. PrECOG aligns with and supports the scientific research goals of ECOG-ACRIN, which has physician leadership overlapping with PrECOG's Board of Managers. PrECOG operates with an operational structure separate from ECOG-ACRIN for all facets of clinical trial management.
• AstraZeneca Pharmaceuticals LP / Medimmune LtdcoreStrategic or Co-development PartnerPrECOG conducted the PrE0505 phase 2 trial with funding from AstraZeneca. Durvalumab (MEDI4736) was evaluated in combination with chemotherapy for malignant pleural mesothelioma. AstraZeneca also supports the DREAM3R phase 3 trial (PrE0506) through Medimmune Ltd, the manufacturer of durvalumab.
• Genentech (Member of Roche Group)coreStrategic or Co-development PartnerPrE0405 trial for mantle cell lymphoma evaluated venetoclax in combination with bendamustine and rituximab. Venetoclax is jointly commercialized by AbbVie and Genentech in the US. The study was supported by Genentech, member of the Roche Group.
• Alliance Foundation Trials (AFT)coreStrategic or Co-development PartnerAFT is co-sponsor of the PALLAS phase 3 trial alongside ABCSG, in collaboration with Pfizer and other groups including PrECOG, NSABP Foundation, BIG, and GBG. AFT and PrECOG enrolled 2,415 patients in the US across 165 sites on the PALLAS study.
• Austrian Breast & Colorectal Cancer Study Group (ABCSG)coreStrategic or Co-development PartnerABCSG is co-sponsor of the PALLAS phase 3 trial. ABCSG enrolled patients in 20 countries outside the U.S. through the BIG network, contributing 3,381 of 5,796 total patients.
• Breast International Group (BIG)coreStrategic or Co-development PartnerBIG is a network of over 55 academic research groups facilitating international breast cancer research. BIG members, including ABCSG and GBG, collaborated on the PALLAS phase 3 trial.
• NSABP Foundation Inc.coreStrategic or Co-development PartnerNSABP Foundation is an academic research organization and collaborator on the PALLAS phase 3 trial, contributing US-based patient enrollment alongside AFT and PrECOG.
• German Breast Group (GBG)coreStrategic or Co-development PartnerGBG is one of the largest academic research organisations devoted to breast cancer worldwide and a founding member of BIG, collaborating on the PALLAS phase 3 trial.
• University of Sydney / NHMRC Clinical Trials CentrecoreStrategic or Co-development PartnerThe University of Sydney, through its NHMRC Clinical Trials Centre, is leading the DREAM3R phase 3 trial in Australia and New Zealand in collaboration with TOGA. PrECOG is sponsoring the US portion. Anna K. Nowak, PhD, is the lead investigator for Australia/New Zealand.
• Thoracic Oncology Group of Australasia (TOGA)coreStrategic or Co-development PartnerTOGA is collaborating with the University of Sydney and PrECOG on the DREAM3R phase 3 trial for malignant pleural mesothelioma, operating sites in Australia and New Zealand.
• Merck KGaA, Darmstadt, GermanycoreStrategic or Co-development PartnerMerck KGaA co-funded the BRACELET-1 (PrE0113) study as part of their partnership with Oncolytics Biotech on the pelareorep development program, providing avelumab (the PD-L1 checkpoint inhibitor used in the study).
• MD Anderson Cancer CentercoreStrategic or Co-development PartnerThe Central Biorepository and Pathology Facility (CBPF) at MD Anderson Cancer Center serves as PrECOG's primary biobank for solid tumors. The Leukemia Bank at MDACC is PrECOG's primary biobank for leukemia trial biospecimens. These biobanks provide high-level services including procurement, collection, processing, preservation, quality control, and distribution of biological materials for clinical translational research.
• Breast Cancer Trials (Australia and New Zealand)coreStrategic or Co-development PartnerBreast Cancer Trials participated as a global sponsor and collaborator in the PATINA phase 3 trial alongside Alliance Foundation Trials, PrECOG, Fondazione Michelangelo, GBG, SOLTI, and Unicancer.
• Fondazione MichelangelocoreStrategic or Co-development PartnerFondazione Michelangelo participated as a global collaborator in the PATINA phase 3 trial for HR+, HER2+ metastatic breast cancer.
• SOLTIcoreStrategic or Co-development PartnerSOLTI participated as a global collaborator in the PATINA phase 3 trial for HR+, HER2+ metastatic breast cancer.
• UnicancercoreStrategic or Co-development PartnerUnicancer participated as a global collaborator in the PATINA phase 3 trial for HR+, HER2+ metastatic breast cancer.
• AbbViecoreStrategic or Co-development PartnerAbbVie jointly develops venetoclax with Genentech and commercializes it in the US and internationally. Venetoclax was evaluated in the PrE0405 trial for mantle cell lymphoma, investigational in this setting.

Scale indicators5 records

Recent moves7 records

Expansion highlights4 records

Direct peers

• ECOG-ACRIN Cancer Research Group: Founding affiliate and parent-adjacent organization of PrECOG; shares scientific committees, board leadership, and trial concept pipeline, and operates a parallel NCI-funded network of academic and community oncology sites.
• Alliance Foundation Trials (AFT): Academic research organization co-sponsoring large multi-center oncology trials (e.g., PALLAS with PrECOG); operates a comparable investigator-initiated, pharma-funded trial model with similar Phase 3 capabilities.
• NSABP Foundation: Long-standing academic research organization focused on breast and colorectal cancer trials; co-collaborator on PALLAS and operates with the same not-for-profit, NCI-network-aligned, pharma-funded model as PrECOG.
• NRG Oncology: Major U.S. NCI-funded cooperative group formed from NSABP, RTOG, and GOG; conducts large multi-center Phase 1–3 oncology trials with academic and community sites, directly comparable in scope and investigator network to PrECOG.
• SWOG Cancer Research Network: NCI-sponsored cooperative group running national multi-center oncology trials; analogous operating model (academic medical centers + community sites + NCTN funding + industry partnerships) that competes with PrECOG for investigator relationships and pharma-sponsored concepts.
• Breast International Group (BIG): Network of 55+ academic research groups coordinating international breast cancer trials; PALLAS and PATINA collaborators with PrECOG and operate the same global, pharma-funded, multi-country Phase 3 model.

Regional players

• German Breast Group (GBG): One of the largest breast cancer-focused academic research organizations globally; co-collaborator on PALLAS and PATINA and a founding BIG member — comparable trial design and pharma-funded operating model, primarily Europe-based.

Emerging players

• Cancer Research UK Clinical Trials Unit: UK-based academic clinical trials unit running multi-center oncology Phase 1–3 studies; shares the not-for-profit, investigator-led, industry-partnered operating model with PrECOG though with geographic and indication differences.

Broad incumbents

• IQVIA Oncology: World's largest commercial CRO with deep oncology trial capabilities; competes with PrECOG for the same pharma-sponsored registration-intent oncology studies but offers far greater scale, technology investment, and global operational infrastructure.
• Syneos Health (now private under Elliott/Veritas): Large global commercial CRO with a significant oncology franchise and biopharma services arm; overlaps with PrECOG's sponsor-facing clinical trial management offerings at much larger scale and broader geographic coverage.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/precogonc
• Facebookfacebook.com/precogonc
• LinkedInlinkedin.com/company/precog-cancer-research-group

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about PrECOG